In contrast, higher expression of NLGN2 was not conductive to the survival of the HER2+ breast cancer patients (HR, 0.59; 95%CI, 0.5 to 0.69; p > 0.05) (Figure 1F). This evidence concerns the gene NLGN2 and breast carcinoma.